Molecular Determinants of Head and Neck Cancer. Cet article n’est pas disponible.Molecular Determinants of Head and Neck Cancer

Summarize the unique pathobiology of head and neck cancers

Addresses signaling pathways and individual proteins that are important in causing or supporting the aggressive nature of head and neck cancer

Discusses the sequencing and epigenomic analysis of the head and neck cancer genome

Focuses on a new understanding of stem cell function in head and neck prognosis and therapy resistance

Discusses a shifting focus of care for HPV positive and HPV negative disease

Addresses rising immunotherapy options, clinical trails and relevant results

Barbara Burtness, M.D. is Professor of Medicine, Yale University School of Medicine and Co-Leader, Developmental Therapeutics Program, Yale Cancer Center. As Chair of the Head and Neck Committee in Eastern Cooperative Oncology Group and a member of the NCI Head and Neck Steering Committee, she helps shape the national agenda for research on all stages of head and neck cancer.

Erica Golemis, Ph.D. is the Deputy Chief Scientific Officer and Co-leader of the Program in Molecular Therapeutics at the Fox Chase Cancer Center. Her research seeks to define the changes in cell signaling that occur as tumors spread by metastasis and develop resistance to drugs, with the ultimate goal of inhibiting these processes to effect disease control and cure.